Moreover, dual targeting of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and PD-1, alongside clinically available TNF inhibitors, enhances macrophage depletion and prevents colitis and hepatitis in vivo [51]. The gene discussed is CTLA4; the disease is colitis.